Craig Underhill

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

Andrew Webb, David Cunningham, J.H. Scarffe et al. · Journal of Clinical Oncology · 1997 · 872 citations

Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17

Stephanie Yasmin Brule, Derek J. Jonker, Christos S. Karapetis et al. · European Journal of Cancer · 2015 · 333 citations

Gastrointestinal Oncology, Prognostic Factor, Medicine +12

Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers

Oliver Klein, Damien Kee, Adnan Nagrial et al. · JAMA Oncology · 2020 · 222 citations · Full text

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Michele Maio, Karl D. Lewis, Lev Demidov et al. · The Lancet Oncology · 2018 · 210 citations · Full text

Medicine, Melanoma, Immunology +10

Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study

C. Kent Osborne, Patrick Neven, Luc Dirix et al. · Clinical Cancer Research · 2011 · 181 citations · Full text